Piceatannol (3,3',4',5-trans-tetrahydroxystilbene) is a polyphenolic compound abundant in the seeds of passion fruit (Passiflora edulis). Piceatannol is an analogue of resveratrol (3,4',5-trans-trihydroxystilbene) and shares the structural motif and biological activities such as activation of SIRT1. Several studies have shown that piceatannol is more potent than resveratrol. In this study, we examined the effects of piceatannol on neural stem cell differentiation into astrocytes compared with those of resveratrol. At a concentration of 2.5 µM, piceatannol promoted astrocyte differentiation, while resveratrol had no effect at this concentration. Furthermore, we found that oral administration of piceatannol increased the number of astrocytes in the brains of adult mice, while resveratrol administration showed no effects. These results suggest that piceatannol has a superior effect to resveratrol in promoting astrocyte differentiation.
Introduction
Piceatannol (3,3′,4′,5-trans-tetrahydroxystilbene) is a natural polyphenolic compound found in a limited number of plants, such as grapes, peanuts, Japanese knotweed, and some berries, and is particularly abundant in passion fruit (Passiflora edulis) seeds. 1 Piceatannol is a 3′-hydroxylated analogue of resveratrol (3,4′,5-trans-trihydroxystilbene). Both piceatannol and resveratrol have been reported to have antioxidative, anti-diabetic, anti-inflammatory, and anti-cancer effects. [2] [3] [4] [5] [6] [7] [8] [9] [10] Furthermore, transcriptional activation of the SIRT1 gene and/or enzymatic activation of the SIRT1 protein promote the activity of SIRT1, an NAD-dependent histone deacetylase. [11] [12] [13] [14] These biological activities are dependent on the similar structures of these molecules (Fig. 1) ; however, interestingly, previous studies have shown that piceatannol is more potent than resveratrol in some aspects. We previously showed that piceatannol is more readily absorbed upon oral ingestion, has higher metabolic stability in vivo, 15 and shows enhanced endothelial nitric oxide synthase 9 and SIRT1 14 expression.
While the physiological effects of piceatannol have been elucidated, its effects on cellular differentiation and the difference between its effects and those of resveratrol are poorly understood. Few studies have examined the effects of piceatannol on cellular differentiation. It was reported that piceatannol and resveratrol induce the differentiation of osteoblasts by increasing bone morphogenetic protein-2 production. [16] [17] [18] Kwon et al. demonstrated that piceatannol inhibited the insulin-signaling pathway and subsequent adipogenesis in the mouse preadipocyte cell line 3T3-L1. 19 Similarly, resveratrol is thought to inhibit the maturation of 3T3-L1 cells through several mechanisms, including by inhibiting insulin signaling. [20] [21] [22] Thus, it is likely that piceatannol and resveratrol share some common effects. It remains unclear whether piceatannol has a specific function in cellular differentiation that is not shared by resveratrol.
Resveratrol induces the differentiation of neural stem cells (NSCs) into astrocytes, 23 the most common glial cells in the central nervous system. Astrocytes have various important roles, including control of blood flow, ion transportation, the uptake and release of neurotransmitters, as well as energy metabolism, thereby regulating brain homeostasis. 24, 25 In this study, we investigated whether piceatannol affects the differentiation of mouse NSCs into astrocytes and compared its effects with those of resveratrol.
Materials and methods

Reagents
Piceatannol and resveratrol were purchased from Tokyo Chemical Industry (Tokyo, Japan). For in vitro experiments, the reagents were dissolved in dimethyl sulfoxide (DMSO) and administered at a final DMSO concentration of less than 0.1%. For ingestion into mice, the reagents were suspended in 0.5% carboxymethyl cellulose solution just prior to use.
In vitro differentiation of astrocytes
The differentiation of mouse embryonic stem cells (ESCs) into astrocytes was conducted as described previously, 26 but with several modifications. The J1 mouse ESC line was obtained from the American Type Culture Collection (Manassas, VA) and maintained on 0.1% gelatin-coated dishes with mitomycin C-treated mouse embryonic fibroblasts (Kitayama Labs, Nagano, Japan 
Flow cytometry
The cells were dispersed in 0.25% trypsin-ethylenediaminetetraacetic acid (Thermo-Fisher Scientific) and transferred into 1.5 mL microcentrifuge tubes. The cells were then fixed using 4% paraformaldehyde at 4°C for 30 min and rinsed with PBS twice. Next, the cells were blocked in PBS with 5% skim milk and 0.2% Triton X-100 at 4°C for 30 min. The cells were labeled in two steps: with the anti-GFAP antibody (1 : 1000) (MAB360, Merck Millipore) at room temperature for 2 h and with the Chromeo 488 goat anti-mouse IgG (1 : 400) (Active Motif ) at 4°C for 30 min. The cells were then subjected to flow cytometry using Cell Sorter SH800 (Sony, Tokyo, Japan). The series of experiments was independently repeated three times to confirm reproducibility.
qPCR analysis
Total RNA was extracted with an RNeasy Plus Mini kit (QIAGEN, Hilden, Germany). Complementary DNA (cDNA) was synthesized from 1 µg of total RNA with the oligo(dT)20 primer and using the PrimeScript II 1st strand cDNA Synthesis Kit (TaKaRa Bio, Shiga, Japan). Real-time PCR analyses were performed on a 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA) using the THUNDERBIRD SYBR qPCR Mix (Toyobo, Osaka, Japan). The primer sequences were as follows: 5′-TGGTGAAGGTCGGTGTGAAC-3′ and 5′-AATGAA-GGGGTCGTTGATGG-3′ for Gapdh, 5′-GCAACCGGGTCAA-GTTGGT-3′ and 5′-GTCGTTGGAGTAGTTGGGGG-3′ for Mash1,
5′-GATGACGATGACAGAACGTCACA-3′
and 5′-GGATCGGT-GCCAATCATGAG-3′ for Sirt1, 5′-CCATTCCTGTACAGA-CTTTCTCCAA-3′ and 5′-GGCCTTCTGACACGGATTTG-3′ for Gfap, and 5′-AACGACAAAATACCTGTGGCCTTG-3′ and 5′-CTCCACTTTGCTCTTGACTTCTATCTTG-3′ for Il1b. A series of experiments, including differentiation, RNA extraction, cDNA synthesis, and qPCR, were independently performed three times, and representative results are shown.
Western blotting
Whole protein of astrocytes was extracted with a sodium dodecyl sulfate (SDS) sample buffer, boiled at 100°C for 5 min, separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred onto an Immobilon P polyvinylidene fluoride (PVDF) membrane (Merck Millipore). The blot was blocked in 10% skim milk in 0.1% Tween/PBS for 60 min, followed by incubation at 4°C overnight with the following primary antibodies: anti-MASH1 ( 
Animal experiments
All experiments were approved by the Committee for Animal Experiments of Waseda University (2015-A067) and performed in accordance with the Guidelines for Proper Conduct of Animal Experiments (Science Council of Japan, 2006). Eightweek-old male BALB/cByJJcl mice were obtained from Clea Japan, Inc. (Tokyo, Japan). The mice were maintained under standard conditions (12-12 h light/dark cycle at 25°C, free access to normal rodent chow (CE-2, Clea Japan) and water) and acclimated to the laboratory conditions for 1 week before experiments. Piceatannol or resveratrol was administered at a volume of 8 mL per kg body weight (BW) by gavage once per day for 2 weeks. The mice were killed on the day after the final administration. For qPCR analyses, the mice were killed by cervical dislocation. Next, the hippocampus was surgically isolated from the brain, snap-frozen immediately in liquid nitrogen, and stored at −80°C. After cryogenic grinding, the tissues were subjected to RNA extraction and the following experiment. Immunohistochemistry was conducted by Genostaff (Tokyo, Japan). Briefly, after perfusion fixation, the brains were dissected and embedded in paraffin. Serial coronal sections including those of the hippocampus were cut at 6 µm. For all sections, the first section in every 10 sections was stained with hematoxylin and eosin, while the second and the fourth sections in every 10 sections were stained with anti-GFAP (Z0334, Dako, Carpinteria, CA) and anti-F4/80 (BM4008, OriGene, Rockville, MD), respectively. Images were obtained with a Leica DM 2500 microscope (Leica Microsystems, Wetzlar, Germany). The positions of the sections in the brain were determined on the basis of the hematoxylin and eosin images to avoid a positional difference between individuals. As a result, seven serial sections were selected from each individual. The number of GFAP-positive stellate cells in the dentate gyrus in each section was determined, and the area of the dentate gyrus was determined using ImageJ software (NIH, Bethesda, MD) to calculate the counts per area. The sum of the values for all 7 sections from one individual was regarded as the relative number of GFAP-positive cells in the dentate gyrus of that individual.
Statistical analysis
Student's t-test was used to determine the statistical significance of the observed differences. Microsoft Excel (Seattle, WA) was used for statistical calculations.
Results
We investigated the effects of piceatannol and resveratrol on astrocyte differentiation using the selective in vitro differentiation model of mouse NSCs into astrocytes. NSCs were prepared from mouse ESCs and were differentiated into astrocytes by culturing them in ACM for 3 days. Immunofluorescence using monoclonal antibodies against the astrocyte marker GFAP selectively labeled cells with a star-like morphology, a characteristic of mature astrocytes ( Fig. 2A, left) . Several studies have reported that GFAP is also expressed in a specific type of NSCs; 27 however, no GFAP expression was detected in undifferentiated NSCs, indicating that the GFAP-positive cells in our experiments were astrocytes. Under the differentiation condition, almost no cells expressed NES, the NSC marker ( Fig. 2A, right) . Initially, piceatannol and resveratrol were added to undifferentiated NSCs at several concentrations. Both compounds exhibited cytotoxicity against NSCs at higher concentrations ( piceatannol, IC 50 = 13.5 µM; resveratrol, IC 50 = 9.2 µM), while no effect was observed at a concentration of 2.5 µM or less (Fig. 2B) . Similarly, when piceatannol and resveratrol were added during differentiation into astrocytes, the number of living cells was significantly reduced at a concentration of 5 µM, but not at 2.5 µM (Fig. 2C) . Therefore, we induced differentiation at lower concentrations (2.5 and 1 µM). We counted the number of total cells (visualized using Hoechst 33342) and astrocytes (i.e., GFAP-positive star-shaped cells) using fluorescent microscopy to estimate the astrocyte differentiation rate. Treatment with 2.5 µM piceatannol significantly increased the number of astrocytes (18 ± 16% increase compared with that in control, p = 0.045). Surprisingly, resveratrol did not affect astrocyte differentiation at either concentration (Fig. 2D) . In addition, differentiated cells treated with 2.5 µM piceatannol or resveratrol were fixed, incubated with the GFAP antibody, and analyzed using flow cytometry. In accordance with the results shown above, the number of GFAP-positive cells increased with the addition of 2.5 µM piceatannol (8 ± 4% increase compared with that in control, p = 0.041) but not by resveratrol (Fig. 2E) .
A previous study suggested that resveratrol leads to the activation of SIRT1 and subsequent repression of the transcription of the Mash1 gene, a target of SIRT1 histone deacetylation. Because MASH1 is a transcription factor that prevents astrocyte differentiation, 23 repression of Mash1 by resveratrol was believed to induce astrocyte differentiation. Because piceatannol, which is similar to resveratrol, is known to activate SIRT1, we investigated whether piceatannol is involved in the silencing of Mash1. NSCs were differentiated into astrocytes by piceatannol and resveratrol at 2.5 µM, and the cells were subsequently harvested and subjected to qPCR analysis. The expression levels of Mash1 were not decreased, but rather slightly increased, in both cases (Fig. 3A) . Thus, in contrast to a previous report, neither piceatannol nor resveratrol repressed the transcription of Mash1 under our experimental conditions. This previous study also showed that pro-oxidative conditions stimulate mRNA expression of Sirt1, thereby promoting astrocyte differentiation. 23 We confirmed that neither piceatannol nor resveratrol altered the expression levels of Sirt1 in astrocytes at 2.5 µM (Fig. 3B ). In addition, MASH1 and SIRT1 were substantially not affected at the protein level (Fig. 3C) . We investigated whether piceatannol promotes the differentiation of the NSCs into astrocytes in the brains of adult mice. We focused on the hippocampus, where adult NSCs reside. Piceatannol was administered orally to adult mice at doses of 3, 10, or 30 mg per kg BW for 2 weeks, and then the hippocampus of the mice was surgically isolated from the brain. The mRNA expression levels of Gfap in the hippocampus were determined by qPCR analysis. Administration of 10 mg per kg BW piceatannol significantly increased the level of Gfap expression in the hippocampus compared with that in vehicleadministered mice (Fig. 4A, p = 0.015) . Administration of 30 mg per kg BW piceatannol also increased the Gfap level, and the effect was slightly lower than that of 10 mg per kg BW, although these differences were not statistically significant ( p = 0.064 versus control and p = 0.246 versus 10 mg per kg BW, respectively). We could not determine whether an excess of piceatannol exerted the opposite effect on NSCs, or if this was simply due to experimental errors. Expression of Mash1 was not substantially affected in any condition (Fig. 4B) . These results suggest that astrocytes were increased by the oral administration of piceatannol. The increase in astrocytes in the hippocampus was also verified by immunohistochemistry. Piceatannol or resveratrol was administered at a dose of 10 mg per kg BW for 2 weeks, and coronal sections of the brain were immunostained with the GFAP antibody to count the number of astrocytes (GFAP-positive star-shaped cells) in the dentate gyrus. We confirmed that the number of astrocytes in the dentate gyrus was increased by piceatannol (23 ± 19% increase compared to that in control, p = 0.050), but not by resveratrol ( Fig. 4C and D) .
It is widely known that CNS damage leads to the activation of astrocytes and subsequent upregulation of GFAP, as a process of inflammation. 28 Thus, we determined whether the increase of GFAP-positive cells was associated with inflammation. Upon CNS damage, reactive microglia accumulate in the damaged site. 29 We examined the expression of F4/80, a marker protein for microglia, and found that there were a few F4/80-positive cells in the median eminence, where the microglia are associated with synaptic remodeling, 30 whereas no F4/ 80-positive cells were observed in the hippocampus of control mice, as well as those of mice administered piceatannol or resveratrol at 10 mg per kg BW (Fig. 5A) . We also examined the expression of Il1b, a gene encoding a precursor of inflammatory cytokine, because mRNA expression of this gene is known to be induced in response to proinflammatory signals. 31 Expression levels of Il1b were not substantially changed in the hippocampus of piceatannol-administered mice at doses of 3, 10, or 30 mg per kg BW, compared with that of control mice (Fig. 5B) . Altogether, we conclude that orally administered piceatannol did not induce inflammation in the hippocampus, and that the increase of the astrocytes was not related to inflammation.
Discussion
In this study, we explored the functional differences between piceatannol and resveratrol in astrocyte differentiation and found that only piceatannol promoted the differentiation of NSCs into astrocytes in vitro. The increase was relatively moderate (8-18%), possibly due to the short-term treatment (72 hours). We also showed that 14 days of oral administration of piceatannol, but not that of resveratrol, increased the number of astrocytes in the hippocampus of adult mice. This is the first report revealing an effect of piceatannol on cellular differentiation that is not shared with resveratrol.
In contrast to a previous report, 23 we observed no positive effect of resveratrol on astrocyte differentiation. Prozorovski et al. exposed mouse fetal NSCs to resveratrol at a concentration of 5 µM. Another group showed that resveratrol was toxic to rat fetal NSCs at 10 µM. They also reported that 3 µM resveratrol was neither toxic nor stimulating for astrocyte differentiation. 32 Our results were consistent with the latter case, i.e., resveratrol was toxic to NSCs at the higher concen- tration (5 µM), whereas it had no effect on differentiation at the lower concentration (2.5 µM). The decrease in the cell number caused by the higher concentration of resveratrol may indirectly influence astrocyte differentiation because the efficiency of differentiation is generally dependent on the cell density. Another possibility is that resveratrol induces upregulation of SIRT1 via a cell-damage pathway. The SIRT1 gene is known to be transcriptionally upregulated by E2F1 upon DNA damage caused by etoposide treatment, to suppress apoptosis. 33 In addition, recent studies showed that at a concentration of 10 µM or more, resveratrol induced DNA doublestrand breaks in normal human cells as well as in tumor cells. 34, 35 Thus, excess resveratrol may induce the expression of SIRT1 by causing DNA damage, thereby repressing the Mash1 gene and facilitating astrocyte differentiation. Importantly, piceatannol promoted astrocyte differentiation at a non-toxic concentration, without the upregulation of Sirt1 or downregulation of Mash1. Piceatannol also did not affect the expression level of Mash1 in the hippocampus, whereas the number of astrocytes increased. This is likely because of different mechanisms, as proposed by Prozorovski et al.; this is important when evaluating its future in vivo applications.
When an interesting effect of a compound is discovered in cultured cells, its effective dose and physiological relevance should be carefully examined in vitro. As described above, several groups showed that both piceatannol and resveratrol inhibit the adipogenesis of 3T3-L1 cells. [19] [20] [21] [22] However, their effective concentrations were 20 µM or greater, which is extremely high compared to the reported maximum plasma concentration in humans after oral intake of 5 g resveratrol. 36 In contrast to these reports, Hu et al. showed that the physiologically achievable level of resveratrol (1 and 10 µM) enhanced the adipogenesis of 3T3-L1 cells. 37 These opposite effects may occur because both resveratrol and piceatannol act on multiple target proteins. Piceatannol is also known as a JAK1/STAT3 inhibitor 38 and STAT3 is essential for astrocyte differentiation, 39 leading to the hypothesis that piceatannol impedes astrocyte differentiation. However, in a previous study, piceatannol was used at 100 µM to diminish the phosphorylation of STAT3 in cultured cells, and phosphorylation was not affected at a concentration of 10 µM. Given that the maximum plasma concentration of piceatannol in rats was no more than 8 µM after oral administration of 88 mg kg −1 of BW, 15 orally ingested piceatannol is likely not sufficient for modulating astrocyte differentiation through the JAK1/STAT3 pathway. Although it remains unknown whether piceatannol can pass through the blood-brain barrier, the effective dose of piceatannol for promoting astrocyte differentiation (2.5 µM) was within the range of its possible plasma concentration. When administered at a physiologically achievable dose, piceatannol did not inhibit the JAK1/STAT3 pathway, but induced astrocyte differentiation through another pathway that is more sensitive to piceatannol. Currently, the molecular mechanism by which piceatannol stimulates astrocyte differentiation remains unclear, but the responsible target molecule appears to be regulated only by piceatannol and not by resveratrol. Our results suggest that this activity is not mediated by SIRT1, a common target of piceatannol and resveratrol. The precise mechanism, particularly the main target of piceatannol in the induction of astrocyte differentiation, requires further analysis. Recent increasing evidence suggests that astrocyte impairment is associated with mental illness. 40 For example, pharmacological lesions of glial cells in the prefrontal cortex of mice caused depression-like behavior, suggesting that a numerical decrease in astrocytes is one of the etiologies of depression. 41 Another study showed that astrocyte function in the hippocampus is required for recovery from depression by pharmacotherapy in rats. 42 Although there are many other factors participating in the onset or exacerbation of depression and mental stress-associated diseases, these reports prompt us to speculate that an increase in astrocytes might be one way to prevent and/or support recovery from these diseases. In this study, we demonstrated that orally administered piceatannol increased astrocytes in the adult hippocampus, implying that piceatannol has a beneficial effect against mental illness. On the basis of the results of our in vitro studies, the intake of piceatannol may result in the differentiation of hippocampal NSCs into astrocytes in vivo. If this is the case, however, whether increasing astrocytes at the expense of the NSCs is beneficial or not should be carefully considered, because the number of adult NSCs, which is also required for neurogenesis, is limited. 43 In future studies, confirming the antistress effects of piceatannol in animals, especially in an astrocyte-impaired model, will solve this question.
In conclusion, piceatannol promoted the differentiation of NSCs into astrocytes at a low, non-toxic, and physiologically achievable dose in vitro, and is likely effective in vivo. This function is not shared by resveratrol, thus, highlighting a novel beneficial effect of piceatannol.
